Novartis Ag (NVS) Total Non-Current Liabilities (2009 - 2026)

Novartis Ag has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $48.3 billion for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 57.83% year-over-year to $48.3 billion; the TTM figure through Jun 2026 stood at $48.3 billion (up 57.83% YoY), while the FY2025 annual figure was $37.1 billion, up 26.15% from the prior year.
• Total Non-Current Liabilities came in at $48.3 billion for Q2 2026 at Novartis Ag, roughly flat from $48.2 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $48.3 billion in Q2 2026 to a low of $25.3 billion in Q1 2024.
• Average Total Non-Current Liabilities over 5 years is $31.9 billion, with a median of $29.7 billion recorded in 2023.
• Year-over-year, Total Non-Current Liabilities declined 19.86% in 2022 and surged 61.47% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $29.4 billion in 2022, then decreased by 8.75% to $26.8 billion in 2023, then advanced by 9.79% to $29.4 billion in 2024, then rose by 26.15% to $37.1 billion in 2025, then soared by 30.22% to $48.3 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $48.3 billion in Q2 2026, $48.2 billion in Q1 2026, and $37.1 billion in Q4 2025.